XML 32 R20.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Supplemental Guarantor Financial Information | 6 Months Ended
--- | ---
Jun. 30, 2018
Condensed Financial Information Disclosure [Abstract] |
Supplemental Guarantor Financial Information | Supplemental Guarantor Financial Information In October 2014, Avanos Medical, Inc.. (referred to below as “Parent”) issued the Notes (described in Note 7, “Debt”). The Notes are guaranteed, jointly and severally by each of our domestic subsidiaries that guarantees the Senior Credit Facilities (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions as defined in the Indenture dated October 17, 2014. Each Guarantor Subsidiary is directly or indirectly 100%-owned by Avanos Medical, Inc. Each of the guarantees of the Notes is a general unsecured obligation of each Guarantor Subsidiary and ranks equally in right of payment with all existing and future indebtedness and all other obligations (except subordinated indebtedness) of each Guarantor Subsidiary. The following condensed consolidating balance sheets as of June 30, 2018 and December 31, 2017, the condensed consolidating statements of income for the three and six months ended June 30, 2018 and 2017 and cash flows for the six months ended June 30, 2018 and 2017 provide condensed consolidating financial information for Avanos Medical, Inc. (“Parent”), the Guarantor Subsidiaries on a combined basis, the non-guarantor subsidiaries on a combined basis and the Parent and its subsidiaries on a consolidated basis. The Parent and the Guarantor Subsidiaries use the equity method of accounting to reflect ownership interests in subsidiaries that are eliminated upon consolidation. Eliminating entries in the following condensed consolidating financial information represent adjustments to (i) eliminate intercompany transactions between or among the Parent, the Guarantor Subsidiaries and the non-guarantor subsidiaries and (ii) eliminate the investments in subsidiaries. AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Three Months Ended June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 169.7 |  |  | $ | 37.1 |  |  | $ | (45.9 | ) |  | $ | 160.9 |
Cost of products sold | (0.8 | ) |  | 89.4 |  |  | 23.5 |  |  | (45.9 | ) |  | 66.2 |
Gross Profit | 0.8 |  |  | 80.3 |  |  | 13.6 |  |  | — |  |  | 94.7 |
Research and development | — |  |  | 10.8 |  |  | — |  |  | — |  |  | 10.8 |
Selling and general expenses | 8.7 |  |  | 59.6 |  |  | 11.5 |  |  | — |  |  | 79.8 |
Other income, net | (2.5 | ) |  | (3.0 | ) |  | (3.2 | ) |  | 4.0 |  |  | (4.7 | )
Operating (Loss) Profit | (5.4 | ) |  | 12.9 |  |  | 5.3 |  |  | (4.0 | ) |  | 8.8 |
Interest income | 1.4 |  |  | 0.1 |  |  | 1.8 |  |  | (1.1 | ) |  | 2.2 |
Interest expense | (10.0 | ) |  | (0.9 | ) |  | (0.1 | ) |  | 1.1 |  |  | (9.9 | )
(Loss) Income Before Income Taxes | (14.0 | ) |  | 12.1 |  |  | 7.0 |  |  | (4.0 | ) |  | 1.1 |
Income tax benefit (provision) | 1.0 |  |  | 1.9 |  |  | (2.7 | ) |  | — |  |  | 0.2 |
Equity in earnings of consolidated subsidiaries | 54.8 |  |  | 132.1 |  |  | — |  |  | (186.9 | ) |  | — |
Net Income from Continuing Operations | 41.8 |  |  | 146.1 |  |  | 4.3 |  |  | (190.9 | ) |  | 1.3 |
(Loss) Income from discontinued operations, net of tax | (6.5 | ) |  | (66.8 | ) |  | 107.3 |  |  | — |  |  | 34.0 |
Net Income | 35.3 |  |  | 79.3 |  |  | 111.6 |  |  | (190.9 | ) |  | 35.3 |
Total other comprehensive loss, net of tax | (10.3 | ) |  | (5.7 | ) |  | (8.8 | ) |  | 14.5 |  |  | (10.3 | )
Comprehensive Income | $ | 25.0 |  |  | $ | 73.6 |  |  | $ | 102.8 |  |  | $ | (176.4 | ) |  | $ | 25.0 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Three Months Ended June 30, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 163.8 |  |  | $ | 80.6 |  |  | $ | (95.3 | ) |  | $ | 149.1 |
Cost of products sold | — |  |  | 96.0 |  |  | 63.9 |  |  | (95.3 | ) |  | 64.6 |
Gross Profit | — |  |  | 67.8 |  |  | 16.7 |  |  | — |  |  | 84.5 |
Research and development | — |  |  | 9.2 |  |  | — |  |  | — |  |  | 9.2 |
Selling and general expenses | 9.7 |  |  | 61.6 |  |  | 9.8 |  |  | — |  |  | 81.1 |
Other expense and (income), net | 0.1 |  |  | 9.2 |  |  | (3.0 | ) |  | — |  |  | 6.3 |
Operating (Loss) Income | (9.8 | ) |  | (12.2 | ) |  | 9.9 |  |  | — |  |  | (12.1 | )
Interest income | 0.2 |  |  | — |  |  | 1.1 |  |  | (0.8 | ) |  | 0.5 |
Interest expense | (8.0 | ) |  | (0.5 | ) |  | (0.1 | ) |  | 0.8 |  |  | (7.8 | )
(Loss) Income Before Income Taxes | (17.6 | ) |  | (12.7 | ) |  | 10.9 |  |  | — |  |  | (19.4 | )
Income tax benefit | 1.3 |  |  | 5.3 |  |  | 1.4 |  |  | — |  |  | 8.0 |
Equity in earnings of consolidated subsidiaries | 28.2 |  |  | 9.9 |  |  | — |  |  | (38.1 | ) |  | — |
Net Income (Loss) from Continuing Operations | 11.9 |  |  | 2.5 |  |  | 12.3 |  |  | (38.1 | ) |  | (11.4 | )
Income from discontinued operations, net of tax | 5.2 |  |  | 19.2 |  |  | 4.1 |  |  | — |  |  | 28.5 |
Net Income | 17.1 |  |  | 21.7 |  |  | 16.4 |  |  | (38.1 | ) |  | 17.1 |
Total other comprehensive income, net of tax | 5.1 |  |  | 3.4 |  |  | 5.2 |  |  | (8.6 | ) |  | 5.1 |
Comprehensive Income | $ | 22.2 |  |  | $ | 25.1 |  |  | $ | 21.6 |  |  | $ | (46.7 | ) |  | $ | 22.2 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Six Months Ended June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 343.0 |  |  | $ | 112.0 |  |  | $ | (137.7 | ) |  | $ | 317.3 |
Cost of products sold | (0.8 | ) |  | 173.9 |  |  | 96.1 |  |  | (137.7 | ) |  | 131.5 |
Gross Profit | 0.8 |  |  | 169.1 |  |  | 15.9 |  |  | — |  |  | 185.8 |
Research and development | — |  |  | 20.7 |  |  | — |  |  | — |  |  | 20.7 |
Selling and general expenses | 20.6 |  |  | 122.0 |  |  | 23.6 |  |  | — |  |  | 166.2 |
Other (income) and expense, net | (2.2 | ) |  | 1.2 |  |  | (5.9 | ) |  | 4.0 |  |  | (2.9 | )
Operating (Loss) Income | (17.6 | ) |  | 25.2 |  |  | (1.8 | ) |  | (4.0 | ) |  | 1.8 |
Interest income | 1.8 |  |  | 0.1 |  |  | 3.2 |  |  | (1.9 | ) |  | 3.2 |
Interest expense | (18.9 | ) |  | (1.6 | ) |  | (0.1 | ) |  | 1.9 |  |  | (18.7 | )
(Loss) Income Before Income Taxes | (34.7 | ) |  | 23.7 |  |  | 1.3 |  |  | (4.0 | ) |  | (13.7 | )
Income tax benefit (provision) | 8.9 |  |  | (1.3 | ) |  | (3.9 | ) |  | — |  |  | 3.7 |
Equity in earnings of consolidated subsidiaries | 87.8 |  |  | 140.6 |  |  | — |  |  | (228.4 | ) |  | — |
Net Income (Loss) from Continuing Operations | 62.0 |  |  | 163.0 |  |  | (2.6 | ) |  | (232.4 | ) |  | (10.0 | )
(Loss) Income from discontinued operations, net of tax | (6.5 | ) |  | (49.9 | ) |  | 121.9 |  |  | — |  |  | 65.5 |
Net Income | 55.5 |  |  | 113.1 |  |  | 119.3 |  |  | (232.4 | ) |  | 55.5 |
Total other comprehensive (loss) income, net of tax | (0.8 | ) |  | 2.8 |  |  | (0.7 | ) |  | (2.1 | ) |  | (0.8 | )
Comprehensive Income | $ | 54.7 |  |  | $ | 115.9 |  |  | $ | 118.6 |  |  | $ | (234.5 | ) |  | $ | 54.7 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Six Months Ended June 30, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 325.9 |  |  | $ | 145.2 |  |  | $ | (176.3 | ) |  | $ | 294.8 |
Cost of products sold | — |  |  | 180.9 |  |  | 124.2 |  |  | (176.3 | ) |  | 128.8 |
Gross Profit | — |  |  | 145.0 |  |  | 21.0 |  |  | — |  |  | 166.0 |
Research and development | — |  |  | 16.5 |  |  | — |  |  | — |  |  | 16.5 |
Selling and general expenses | 19.7 |  |  | 125.6 |  |  | 20.6 |  |  | — |  |  | 165.9 |
Other expense and (income), net | 0.3 |  |  | 18.8 |  |  | (5.8 | ) |  | — |  |  | 13.3 |
Operating (Loss) Profit | (20.0 | ) |  | (15.9 | ) |  | 6.2 |  |  | — |  |  | (29.7 | )
Interest income | 0.4 |  |  | — |  |  | 2.1 |  |  | (1.6 | ) |  | 0.9 |
Interest expense | (15.8 | ) |  | (1.1 | ) |  | (0.1 | ) |  | 1.6 |  |  | (15.4 | )
(Loss) Income Before Income Taxes | (35.4 | ) |  | (17.0 | ) |  | 8.2 |  |  | — |  |  | (44.2 | )
Income tax benefit | 2.5 |  |  | 14.5 |  |  | 0.9 |  |  | — |  |  | 17.9 |
Equity in earnings of consolidated subsidiaries | 52.1 |  |  | 13.0 |  |  | — |  |  | (65.1 | ) |  | — |
Net Income (Loss) from Continuing Operations | 19.2 |  |  | 10.5 |  |  | 9.1 |  |  | (65.1 | ) |  | (26.3 | )
Income from discontinued operations, net of tax | 10.7 |  |  | 35.7 |  |  | 9.8 |  |  | — |  |  | 56.2 |
Net Income | 29.9 |  |  | 46.2 |  |  | 18.9 |  |  | (65.1 | ) |  | 29.9 |
Total other comprehensive income, net of tax | 15.8 |  |  | 11.9 |  |  | 14.9 |  |  | (26.8 | ) |  | 15.8 |
Comprehensive Income | $ | 45.7 |  |  | $ | 58.1 |  |  | $ | 33.8 |  |  | $ | (91.9 | ) |  | $ | 45.7 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 109.9 |  |  | $ | 77.7 |  |  | $ | 292.0 |  |  | $ | — |  |  | $ | 479.6 |
Restricted cash | 51.5 |  |  | — |  |  | — |  |  | — |  |  | 51.5 |
Accounts receivable, net of allowances | 2.2 |  |  | 1,074.7 |  |  | 208.7 |  |  | (1,096.4 | ) |  | 189.2 |
Inventories | — |  |  | 92.9 |  |  | 14.9 |  |  | — |  |  | 107.8 |
Prepaid expenses and other current assets | 11.9 |  |  | 15.8 |  |  | 29.2 |  |  | (8.5 | ) |  | 48.4 |
Total Current Assets | 175.5 |  |  | 1,261.1 |  |  | 544.8 |  |  | (1,104.9 | ) |  | 876.5 |
Property, Plant and Equipment, net | — |  |  | 104.5 |  |  | 19.0 |  |  | — |  |  | 123.5 |
Investment in Consolidated Subsidiaries | 2,303.7 |  |  | 475.7 |  |  | — |  |  | (2,779.4 | ) |  | — |
Goodwill | — |  |  | 738.1 |  |  | 25.7 |  |  | — |  |  | 763.8 |
Other Intangible Assets, net | — |  |  | 130.6 |  |  | 8.9 |  |  | — |  |  | 139.5 |
Other Assets | 0.1 |  |  | 9.6 |  |  | 4.4 |  |  | — |  |  | 14.1 |
TOTAL ASSETS | $ | 2,479.3 |  |  | $ | 2,719.6 |  |  | $ | 602.8 |  |  | $ | (3,884.3 | ) |  | $ | 1,917.4 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Trade accounts payable | $ | 930.6 |  |  | $ | 286.1 |  |  | $ | 46.7 |  |  | $ | (1,086.5 | ) |  | $ | 176.9 |
Accrued expenses | 6.4 |  |  | 160.0 |  |  | 27.9 |  |  | (18.4 | ) |  | 175.9 |
Total Current Liabilities | 937.0 |  |  | 446.1 |  |  | 74.6 |  |  | (1,104.9 | ) |  | 352.8 |
Long-Term Debt | 247.4 |  |  | — |  |  | — |  |  | — |  |  | 247.4 |
Other Long-Term Liabilities | 8.3 |  |  | 18.8 |  |  | 3.5 |  |  | — |  |  | 30.6 |
Total Liabilities | 1,192.7 |  |  | 464.9 |  |  | 78.1 |  |  | (1,104.9 | ) |  | 630.8 |
Total Equity | 1,286.6 |  |  | 2,254.7 |  |  | 524.7 |  |  | (2,779.4 | ) |  | 1,286.6 |
TOTAL LIABILITIES AND EQUITY | $ | 2,479.3 |  |  | $ | 2,719.6 |  |  | $ | 602.8 |  |  | $ | (3,884.3 | ) |  | $ | 1,917.4 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 114.5 |  |  | $ | 16.0 |  |  | $ | 89.2 |  |  | $ | — |  |  | $ | 219.7 |
Accounts receivable, net of allowances | 1.1 |  |  | 623.0 |  |  | 266.3 |  |  | (687.4 | ) |  | 203.0 |
Inventories | — |  |  | 76.0 |  |  | 15.1 |  |  | — |  |  | 91.1 |
Prepaid expenses and other current assets | 0.6 |  |  | 11.7 |  |  | 2.1 |  |  | — |  |  | 14.4 |
Assets held for sale | 0.3 |  |  | 546.7 |  |  | 85.5 |  |  | — |  |  | 632.5 |
Total Current Assets | 116.5 |  |  | 1,273.4 |  |  | 458.2 |  |  | (687.4 | ) |  | 1,160.7 |
Property, Plant and Equipment, net | — |  |  | 92.9 |  |  | 17.0 |  |  | — |  |  | 109.9 |
Investment in Consolidated Subsidiaries | 2,154.3 |  |  | 403.2 |  |  | — |  |  | (2,557.5 | ) |  | — |
Goodwill | — |  |  | 738.1 |  |  | 26.6 |  |  | — |  |  | 764.7 |
Other Intangible Assets, net | — |  |  | 139.5 |  |  | 9.4 |  |  | — |  |  | 148.9 |
Other Assets | 0.3 |  |  | 6.0 |  |  | 5.4 |  |  | — |  |  | 11.7 |
TOTAL ASSETS | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Current portion of long-term debt | $ | 39.8 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 39.8 |
Trade accounts payable | 454.0 |  |  | 347.0 |  |  | 49.8 |  |  | (679.6 | ) |  | 171.2 |
Accrued expenses | 11.6 |  |  | 113.9 |  |  | 27.4 |  |  | (8.0 | ) |  | 144.9 |
Liabilities held for sale | — |  |  | 7.8 |  |  | 26.1 |  |  | — |  |  | 33.9 |
Total Current Liabilities | 505.4 |  |  | 468.7 |  |  | 103.3 |  |  | (687.6 | ) |  | 389.8 |
Long-Term Debt | 541.1 |  |  | — |  |  | — |  |  | — |  |  | 541.1 |
Other Long-Term Liabilities | 9.2 |  |  | 36.1 |  |  | 4.3 |  |  | — |  |  | 49.6 |
Total Liabilities | 1,055.7 |  |  | 504.8 |  |  | 107.6 |  |  | (687.6 | ) |  | 980.5 |
Total Equity | 1,215.4 |  |  | 2,148.3 |  |  | 409.0 |  |  | (2,557.3 | ) |  | 1,215.4 |
TOTAL LIABILITIES AND EQUITY | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Six Months Ended June 30, 2018
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (114.2 | ) |  | $ | 31.3 |  |  | $ | 12.5 |  |  | $ | — |  |  | $ | (70.4 | )
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (15.0 | ) |  | (5.7 | ) |  | — |  |  | (20.7 | )
Proceeds from the Divestiture | 521.6 |  |  | 9.0 |  |  | 203.9 |  |  | — |  |  | 734.5 |
Intercompany contributions | — |  |  | 36.3 |  |  | — |  |  | (36.3 | ) |  | — |
Cash Provided by Investing Activities | 521.6 |  |  | 30.3 |  |  | 198.2 |  |  | (36.3 | ) |  | 713.8 |
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | (32.3 | ) |  | — |  |  | (4.0 | ) |  | 36.3 |  |  | — |
Debt repayments | (339.0 | ) |  | — |  |  | — |  |  | — |  |  | (339.0 | )
Purchase of treasury stock | (0.6 | ) |  | — |  |  | — |  |  | — |  |  | (0.6 | )
Proceeds from the exercise of stock options | 11.4 |  |  | — |  |  | — |  |  | — |  |  | 11.4 |
Cash Used in Financing Activities | (360.5 | ) |  | — |  |  | (4.0 | ) |  | 36.3 |  |  | (328.2 | )
Effect of Exchange Rate on Cash, Cash Equivalents and Restricted Cash | — |  |  | 0.1 |  |  | (3.9 | ) |  | — |  |  | (3.8 | )
Increase in Cash, Cash Equivalents and Restricted Cash | 46.9 |  |  | 61.7 |  |  | 202.8 |  |  | — |  |  | 311.4 |
Cash and Cash Equivalents, Beginning of Period | 114.5 |  |  | 16.0 |  |  | 89.2 |  |  | — |  |  | 219.7 |
Cash, Cash Equivalents and Restricted Cash, End of Period | $ | 161.4 |  |  | $ | 77.7 |  |  | $ | 292.0 |  |  | $ | — |  |  | $ | 531.1 |
AVANOS MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Six Months Ended June 30, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (21.1 | ) |  | $ | 73.7 |  |  | $ | 4.1 |  |  | $ | — |  |  | $ | 56.7 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (13.0 | ) |  | (3.6 | ) |  | — |  |  | (16.6 | )
Proceeds from property dispositions | — |  |  | 0.1 |  |  | — |  |  | — |  |  | 0.1 |
Intercompany contributions | — |  |  | (55.1 | ) |  | — |  |  | 55.1 |  |  | — |
Cash Used in Investing Activities | — |  |  | (68.0 | ) |  | (3.6 | ) |  | 55.1 |  |  | (16.5 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 57.8 |  |  | — |  |  | (2.7 | ) |  | (55.1 | ) |  | — |
Purchase of treasury stock | (2.0 | ) |  | — |  |  | — |  |  | — |  |  | (2.0 | )
Proceeds from the exercise of stock options | 0.8 |  |  | — |  |  | — |  |  | — |  |  | 0.8 |
Cash Provided by (Used in) Financing Activities | 56.6 |  |  | — |  |  | (2.7 | ) |  | (55.1 | ) |  | (1.2 | )
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | 0.3 |  |  | 1.8 |  |  | — |  |  | 2.1 |
Increase (Decrease) in Cash and Cash Equivalents | 35.5 |  |  | 6.0 |  |  | (0.4 | ) |  | — |  |  | 41.1 |
Cash and Cash Equivalents, Beginning of Period | 54.2 |  |  | 9.5 |  |  | 50.0 |  |  | — |  |  | 113.7 |
Cash and Cash Equivalents, End of Period | $ | 89.7 |  |  | $ | 15.5 |  |  | $ | 49.6 |  |  | $ | — |  |  | $ | 154.8 |

X
- References No definition available. + Details
Name: | srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 2 -Subparagraph (SX 210.9-06) -URI http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884 + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration